Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.

Study Overview

• Status: Completed
• Conditions: Melanoma
• Intervention / Treatment: Drug: Dabrafenib; Drug: Trametinib; Drug: Vemurafenib

Detailed Description

Screening/Subject eligibility: Subjects with histologically confirmed cutaneous melanoma that was either unresectable or metastatic (Stages IIIC or IV), were screened for eligibility. Eligible subjects were BRAF V600E or V600K mutation positive. Subjects who had prior systemic anti-cancer treatment in the advanced or metastatic setting were not eligible although prior systemic treatment in the adjuvant setting was allowed.

Randomization: A total of 704 subjects were randomized in a ratio of 1:1 to receive combination therapy (352 subjects) or vemurafenib treatment (352 subjects). Subjects were stratified by LDH level (> the ULN versus =< ULN) and BRAF mutation (V600E versus V600K).

Study treatment: Dabrafenib and trametinib were administered orally at their recommended doses of 150 mg b.i.d. and 2.0 mg once daily, respectively. Subjects randomized in the combination therapy arm received both the agents. Subjects randomized in the vemurafenib arm received vemurafenib at the recommended dose of 960 mg orally b.i.d. Subjects in both the arms continued treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent. The protocol was amended on 07-Aug-2014 which allowed subjects who were still receiving vemurafenib to cross over to the dabrafenib and trametinib combination arm, including those subjects who were still receiving vemurafenib monotherapy treatment after disease progression. A washout period of a minimum of 7 days was considered prior to initiating dabrafenib in combination with trametinib. Subjects who experienced disease progression on the vemurafenib monotherapy arm, discontinued vemurafenib monotherapy, and subsequently received another anticancer therapy were ineligible for cross over to the dabrafenib and trametinib combination arm.

Follow-up/Study closure: After study treatment discontinuation, subjects were followed for survival and disease progression as applicable. This study completed once all the subjects had at least the 5-years of follow-up.

• Study Type: Interventional
• Enrollment (Actual): 704
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina, C1121ABE
    • Novartis Investigative Site
  • San Miguel de Tucuman, Argentina, T4000IAK
    • Novartis Investigative Site
  • Santa Fe, Argentina, 3000
    • Novartis Investigative Site
  • Buenos Aires
    • Capital Federal, Buenos Aires, Argentina, C1426ANZ
      • Novartis Investigative Site
  • Río Negro
    • Viedma, Río Negro, Argentina, R8500ACE
      • Novartis Investigative Site
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000KZE
      • Novartis Investigative Site
• Australia
  • New South Wales
    • North Sydney, New South Wales, Australia, 2060
      • Novartis Investigative Site
    • Westmead, New South Wales, Australia, 2145
      • Novartis Investigative Site
  • Queensland
    • Greenslopes, Queensland, Australia, 4120
      • Novartis Investigative Site
    • Herston, Queensland, Australia, 4029
      • Novartis Investigative Site
    • South Brisbane, Queensland, Australia, 4101
      • Novartis Investigative Site
  • South Australia
    • Woodville, South Australia, Australia, 5011
      • Novartis Investigative Site
  • Victoria
    • Box Hill, Victoria, Australia, 3128
      • Novartis Investigative Site
    • Melbourne, Victoria, Australia, 3004
      • Novartis Investigative Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Novartis Investigative Site
• Austria
  • Graz, Austria, A-8036
    • Novartis Investigative Site
  • Innsbruck, Austria, 6020
    • Novartis Investigative Site
  • Salzburg, Austria, A-5020
    • Novartis Investigative Site
  • Wien, Austria, 1090
    • Novartis Investigative Site
  • Wien, Austria, A-1030
    • Novartis Investigative Site
• Belgium
  • Brasschaat, Belgium, 2930
    • Novartis Investigative Site
  • Brussel, Belgium, 1090
    • Novartis Investigative Site
  • Brussels, Belgium, 1200
    • Novartis Investigative Site
  • Gent, Belgium, 9000
    • Novartis Investigative Site
  • Kortrijk, Belgium, 8500
    • Novartis Investigative Site
  • Leuven, Belgium, 3000
    • Novartis Investigative Site
  • Namur, Belgium, 5000
    • Novartis Investigative Site
  • Wilrijk, Belgium, 2610
    • Novartis Investigative Site
• Brazil
  • Sao Paulo - SP, Brazil, 01323-900
    • Novartis Investigative Site
  • Rio Grande Do Sul
    • Ijui, Rio Grande Do Sul, Brazil, 98700-000
      • Novartis Investigative Site
  • Santa Catarina
    • Itajai, Santa Catarina, Brazil, 88301-215
      • Novartis Investigative Site
• Canada
  • Quebec, Canada, G1R 2J6
    • Novartis Investigative Site
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N2
      • Novartis Investigative Site
  • British Columbia
    • Kelowna, British Columbia, Canada, V1Y 5L3
      • Novartis Investigative Site
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • Novartis Investigative Site
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3E 0V9
      • Novartis Investigative Site
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 2Y9
      • Novartis Investigative Site
  • Ontario
    • Kingston, Ontario, Canada, K7L 5P9
      • Novartis Investigative Site
    • Oshawa, Ontario, Canada, L1G 2B9
      • Novartis Investigative Site
    • Ottawa, Ontario, Canada, K1H 8L6
      • Novartis Investigative Site
    • Toronto, Ontario, Canada, M5G 2M9
      • Novartis Investigative Site
    • Toronto, Ontario, Canada, M4N 3M5
      • Novartis Investigative Site
  • Quebec
    • Montreal, Quebec, Canada, H2L 4M1
      • Novartis Investigative Site
• Czechia
  • Olomouc, Czechia, 775 20
    • Novartis Investigative Site
  • Ostrava, Czechia, 708 52
    • Novartis Investigative Site
  • Praha 10, Czechia, 100 34
    • Novartis Investigative Site
  • Praha 2, Czechia, 128 08
    • Novartis Investigative Site
  • Zlin, Czechia, 76275
    • Novartis Investigative Site
• Denmark
  • Arhus C, Denmark, 8000
    • Novartis Investigative Site
  • Herlev, Denmark, 2730
    • Novartis Investigative Site
  • Odense, Denmark, 5000 C
    • Novartis Investigative Site
• Finland
  • Helsinki, Finland, 00029
    • Novartis Investigative Site
  • Jyvaskyla, Finland, 40620
    • Novartis Investigative Site
  • Tampere, Finland, 33520
    • Novartis Investigative Site
  • Turku, Finland, 20520
    • Novartis Investigative Site
• France
  • Bordeaux, France, 33075
    • Novartis Investigative Site
  • Grenoble, France, 38043
    • Novartis Investigative Site
  • Lille, France, 59037
    • Novartis Investigative Site
  • Marseille cedex 5, France, 13385
    • Novartis Investigative Site
  • Montpellier cedex 5, France, 34295
    • Novartis Investigative Site
  • Nantes, France, 44093
    • Novartis Investigative Site
  • Nice, France, 06202
    • Novartis Investigative Site
  • Paris Cedex 10, France, 75475
    • Novartis Investigative Site
  • Reims Cedex, France, 51092
    • Novartis Investigative Site
  • Rennes Cedex, France, 35042
    • Novartis Investigative Site
  • Villejuif cedex, France, 94805
    • Novartis Investigative Site
• Germany
  • Baden-Wuerttemberg
    • Heidelberg, Baden-Wuerttemberg, Germany, 69120
      • Novartis Investigative Site
    • Heilbronn, Baden-Wuerttemberg, Germany, 74078
      • Novartis Investigative Site
    • Mannheim, Baden-Wuerttemberg, Germany, 68167
      • Novartis Investigative Site
    • Tuebingen, Baden-Wuerttemberg, Germany, 72076
      • Novartis Investigative Site
  • Bayern
    • Erlangen, Bayern, Germany, 91054
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 80337
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 80804
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 80802
      • Novartis Investigative Site
    • Nuernberg, Bayern, Germany, 90419
      • Novartis Investigative Site
    • Regensburg, Bayern, Germany, 93053
      • Novartis Investigative Site
    • Wuerzburg, Bayern, Germany, 97080
      • Novartis Investigative Site
  • Niedersachsen
    • Buxtehude, Niedersachsen, Germany, 21614
      • Novartis Investigative Site
    • Hannover, Niedersachsen, Germany, 30625
      • Novartis Investigative Site
  • Nordrhein-Westfalen
    • Bonn, Nordrhein-Westfalen, Germany, 53127
      • Novartis Investigative Site
    • Essen, Nordrhein-Westfalen, Germany, 45122
      • Novartis Investigative Site
    • Koeln, Nordrhein-Westfalen, Germany, 50937
      • Novartis Investigative Site
  • Rheinland-Pfalz
    • Ludwigshafen, Rheinland-Pfalz, Germany, 67063
      • Novartis Investigative Site
    • Mainz, Rheinland-Pfalz, Germany, 55131
      • Novartis Investigative Site
  • Sachsen
    • Dresden, Sachsen, Germany, 01307
      • Novartis Investigative Site
    • Leipzig, Sachsen, Germany, 04103
      • Novartis Investigative Site
  • Sachsen-Anhalt
    • Magdeburg, Sachsen-Anhalt, Germany, 39120
      • Novartis Investigative Site
  • Schleswig-Holstein
    • Kiel, Schleswig-Holstein, Germany, 24105
      • Novartis Investigative Site
    • Luebeck, Schleswig-Holstein, Germany, 23538
      • Novartis Investigative Site
  • Thueringen
    • Erfurt, Thueringen, Germany, 99089
      • Novartis Investigative Site
    • Gera, Thueringen, Germany, 07548
      • Novartis Investigative Site
• Hungary
  • Budapest, Hungary, H-1122
    • Novartis Investigative Site
  • Budapest, Hungary, 1062
    • Novartis Investigative Site
  • Debrecen, Hungary, 4032
    • Novartis Investigative Site
  • Gyor, Hungary, H-9024
    • Novartis Investigative Site
  • Kaposvar, Hungary, 7400
    • Novartis Investigative Site
  • Miskolc, Hungary, 3526
    • Novartis Investigative Site
  • Szeged, Hungary, 6720
    • Novartis Investigative Site
• Ireland
  • Co.Cork, Ireland
    • Novartis Investigative Site
  • Dublin, Ireland, 7
    • Novartis Investigative Site
  • Dublin, Ireland, 9
    • Novartis Investigative Site
  • Dublin, Ireland, 4
    • Novartis Investigative Site
  • Galway, Ireland
    • Novartis Investigative Site
• Israel
  • Jerusalem, Israel
    • Novartis Investigative Site
  • Ramat Gan, Israel, 52621
    • Novartis Investigative Site
• Italy
  • Campania
    • Napoli, Campania, Italy, 80131
      • Novartis Investigative Site
  • Lazio
    • Roma, Lazio, Italy, 00167
      • Novartis Investigative Site
  • Liguria
    • Genova, Liguria, Italy, 16132
      • Novartis Investigative Site
  • Lombardia
    • Bergamo, Lombardia, Italy, 24128
      • Novartis Investigative Site
    • Milano, Lombardia, Italy, 20133
      • Novartis Investigative Site
    • Milano, Lombardia, Italy, 20141
      • Novartis Investigative Site
  • Toscana
    • Pisa, Toscana, Italy, 56126
      • Novartis Investigative Site
  • Veneto
    • Padova, Veneto, Italy, 35128
      • Novartis Investigative Site
• Korea, Republic of
  • Goyang-si, Gyeonggi-Do, Korea, Republic of, 410-769
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 03080
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 135-710
    • Novartis Investigative Site
• Netherlands
  • Amsterdam, Netherlands, 1066 CX
    • Novartis Investigative Site
  • Amsterdam, Netherlands, 1081 HV
    • Novartis Investigative Site
  • Groningen, Netherlands, 9713 GZ
    • Novartis Investigative Site
  • Leeuwarden, Netherlands, 8934 AD
    • Novartis Investigative Site
  • Leiden, Netherlands, 2333 ZA
    • Novartis Investigative Site
  • Rotterdam, Netherlands, 3015 GD
    • Novartis Investigative Site
• New Zealand
  • Christchurch, New Zealand, 8011
    • Novartis Investigative Site
  • Newtown, Wellington, New Zealand, 6002
    • Novartis Investigative Site
• Norway
  • Kristiansand, Norway, 4604
    • Novartis Investigative Site
  • Lorenskog, Norway, 1478
    • Novartis Investigative Site
  • Oslo, Norway, 0310
    • Novartis Investigative Site
• Poland
  • Gdansk, Poland, 80-215
    • Novartis Investigative Site
  • Konin, Poland, 62-500
    • Novartis Investigative Site
  • Poznan, Poland, 60-693
    • Novartis Investigative Site
  • Warszawa, Poland, 02-781
    • Novartis Investigative Site
• Russian Federation
  • Chelyabinsk, Russian Federation, 454087
    • Novartis Investigative Site
  • Magnitogorsk, Russian Federation, 455001
    • Novartis Investigative Site
  • Moscow, Russian Federation, 115478
    • Novartis Investigative Site
  • Moscow, Russian Federation, 143423
    • Novartis Investigative Site
  • Nizhniy Novgorod, Russian Federation, 603081
    • Novartis Investigative Site
  • Ryazan, Russian Federation, 390011
    • Novartis Investigative Site
  • St. Petersburg, Russian Federation, 197758
    • Novartis Investigative Site
• Spain
  • Barcelona, Spain, 08036
    • Novartis Investigative Site
  • Hospitalet de Llobregat, Barcelona, Spain, 08907
    • Novartis Investigative Site
  • Las Palmas De Gran Canaria, Spain, 35016
    • Novartis Investigative Site
  • Madrid, Spain, 28007
    • Novartis Investigative Site
  • Madrid, Spain, 28050
    • Novartis Investigative Site
  • Palma de Mallorca, Spain, 07010
    • Novartis Investigative Site
  • Pamplona, Spain, 31008
    • Novartis Investigative Site
  • Valencia, Spain, 46014
    • Novartis Investigative Site
  • Valencia, Spain, 46009
    • Novartis Investigative Site
• Sweden
  • Linkoping, Sweden, SE-581 85
    • Novartis Investigative Site
  • Umea, Sweden, SE-901 85
    • Novartis Investigative Site
• Switzerland
  • Basel, Switzerland, 4031
    • Novartis Investigative Site
  • Lausanne, Switzerland, 1011
    • Novartis Investigative Site
  • Zurich, Switzerland, 8091
    • Novartis Investigative Site
• Taiwan
  • Tainan, Taiwan, 704
    • Novartis Investigative Site
  • Taipei, Taiwan, 100
    • Novartis Investigative Site
  • Taoyuan, Taiwan, 333
    • Novartis Investigative Site
• Ukraine
  • Dnipropetrovsk, Ukraine, 49102
    • Novartis Investigative Site
  • Donetsk, Ukraine, 83092
    • Novartis Investigative Site
  • Kharkiv, Ukraine, 61070
    • Novartis Investigative Site
  • Kyiv, Ukraine, 03022
    • Novartis Investigative Site
  • Lviv, Ukraine, 79031
    • Novartis Investigative Site
  • Sumy, Ukraine, 40005
    • Novartis Investigative Site
  • Uzhgorod, Ukraine, 88017
    • Novartis Investigative Site
• United Kingdom
  • Cambridge, United Kingdom, CB2 0QQ
    • Novartis Investigative Site
  • Glasgow, United Kingdom, G12 0YN
    • Novartis Investigative Site
  • London, United Kingdom, NW3 2QG
    • Novartis Investigative Site
  • London, United Kingdom, SE1 7EH
    • Novartis Investigative Site
  • Manchester, United Kingdom, M20 4BX
    • Novartis Investigative Site
  • Southampton, United Kingdom, SO16 6YD
    • Novartis Investigative Site
  • Swansea, United Kingdom, SA2 8QA
    • Novartis Investigative Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35243
      • Novartis Investigative Site
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Novartis Investigative Site
  • California
    • Beverly Hills, California, United States, 90211
      • Novartis Investigative Site
    • San Francisco, California, United States, 94115
      • Novartis Investigative Site
    • Vallejo, California, United States, 94589
      • Novartis Investigative Site
  • Colorado
    • Aurora, Colorado, United States, 80010
      • Novartis Investigative Site
  • Florida
    • Jacksonville, Florida, United States, 32204
      • Novartis Investigative Site
    • Miami Beach, Florida, United States, 33140
      • Novartis Investigative Site
    • Orlando, Florida, United States, 32804
      • Novartis Investigative Site
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Novartis Investigative Site
    • Atlanta, Georgia, United States, 30341
      • Novartis Investigative Site
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Novartis Investigative Site
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Novartis Investigative Site
  • Minnesota
    • Fridley, Minnesota, United States, 55432
      • Novartis Investigative Site
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Novartis Investigative Site
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • Novartis Investigative Site
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Novartis Investigative Site
    • New Brunswick, New Jersey, United States, 08901
      • Novartis Investigative Site
  • New York
    • New York, New York, United States, 10029
      • Novartis Investigative Site
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599-7600
      • Novartis Investigative Site
    • Charlotte, North Carolina, United States, 28204
      • Novartis Investigative Site
    • Durham, North Carolina, United States, 27710
      • Novartis Investigative Site
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • Novartis Investigative Site
    • Columbus, Ohio, United States, 43210
      • Novartis Investigative Site
  • Oregon
    • Bend, Oregon, United States, 97701
      • Novartis Investigative Site
    • Portland, Oregon, United States, 97213
      • Novartis Investigative Site
    • Portland, Oregon, United States, 97239
      • Novartis Investigative Site
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Novartis Investigative Site
    • Greenville, South Carolina, United States, 29605
      • Novartis Investigative Site
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Novartis Investigative Site
  • Texas
    • Dallas, Texas, United States, 75246
      • Novartis Investigative Site
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Novartis Investigative Site
    • Salt Lake City, Utah, United States, 84112-5550
      • Novartis Investigative Site
  • Vermont
    • Burlington, Vermont, United States, 05403
      • Novartis Investigative Site
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • Novartis Investigative Site
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• >= 18 years of age
• Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
• Measurable disease according to RECIST 1.1
• Women of childbearing potential with negative serum pregnancy test prior to randomisation
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Adequate baseline organ function

Key Exclusion Criteria:

• Any prior use of a BRAF or MEK inhibitor
• Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed
• History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)
• Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
• Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisation
• History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
• History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dabrafenib plus Trametinib; BRAF inhibitor plus MEK inhibitor	Drug: Dabrafenib; Dabrafenib 150 mg twice daily orally; Other Names: GSK2118436; Drug: Trametinib; Trametinib 2 mg once daily orally; Other Names: GSK1120212
Active Comparator: Vemurafenib; BRAF inhibitor	Drug: Vemurafenib; Vemurafenib 960 mg twice daily orally; Other Names: Monotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Overall Survival (OS) was defined as the interval of time between the date of randomization and the date of death due to any cause. For patients who did not die, OS was censored at the date of last contact.	From the date of randomization until date of death due to any cause (up to approximately 6 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS), as Assessed by the Investigator	Progression-free survival (PFS) was defined as the interval of time between the date of randomization and the first documented occurrence of disease progression or death due to any cause. PFS for investigator-assessed response was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.	From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator	Overall response was defined as the percentage of confirmed responders (complete response [CR] + partial response [PR] per RECIST, Version 1.1) as summarized by Investigator assessment. CR was defined as the disappearance of all evidence of target lesions. PR was defined as at least a 30% reduction from Baseline in the sum of the longest diameter (LD) of all target lesions. Data were reported as those participants with measureable disease at Baseline.	From randomization until the first documented complete response or partial response (up to approximately 6 years)
Duration of Response (DOR), as Assessed by the Investigator	Duration of Response (DOR) was defined as the time from the first documented evidence of a CR (disappearance of all evidence of target lesions) or a PR (at least a 30% reduction from Baseline in the sum of the longest diameter of all target lesions) until disease progression or death due to any cause. PD was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of at least1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Data were summarized per RECIST, Version 1.1.	From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2.
• Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandala M, Haanen JBAG, Lebbe C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
• Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16.
• Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2012
• Primary Completion (Actual): April 17, 2014
• Study Completion (Actual): April 25, 2019

Study Registration Dates

• First Submitted: May 10, 2012
• First Submitted That Met QC Criteria: May 10, 2012
• First Posted (Estimate): May 14, 2012

Study Record Updates

• Last Update Posted (Actual): February 24, 2021
• Last Update Submitted That Met QC Criteria: February 8, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: Cancer; MEK inhibitor; BRAF inhibitor; Metastatic Melanoma
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Trametinib; Dabrafenib; Vemurafenib
• Other Study ID Numbers: 116513; CDRB436B2302 (Other Identifier: Novartis); 2011-006088-23 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes

IPD Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No